Time filter

Source Type

News Article | May 9, 2017
Site: www.prnewswire.com

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 144-page report you will receive 150 charts - all unavailable elsewhere. The 144-page report provides clear detailed insight into the global clinical nutrition market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. • This report also shows forecast revenue to 2027 for the leading segments and sub segments of the clinical nutrition market: • Our analyses show individual revenue forecasts to 2027 for these regional and national markets: - North America: the US and Rest of North America - Europe: Germany, France, the UK and Rest of Europe - Asia-Pacific: China, Japan, India and Rest of Asia-Pacific - Rest of the World (RoW): Middle East and Rest of RoW Each regional market is further segmented into the leading segments and sub segments of the clinical nutrition market. Whereas, each national market is further segmented into the leading segments of the clinical nutrition market. • This report discusses the leading companies that hold the majority of market shares in the clinical nutrition market: - Baxter International. NYSE: BAX - Abbott Laboratories. NYSE: ABT - B. Braun Melsungen AG. - Nestle S.A. VTX: NESN - Groupe Danone. EPA: BN - Mead Johnson. NYSE: MJN - Fresenius Kabi. ETR: FRE - Hospira. NYSE: HSP - Perrigo. TLV: PRGO • This report also discusses Porter's Five Forces Analysis. These forces analyze the clinical nutrition market from five different perspectives such as competitive rivalry within the industry; threat of new entrants; bargaining power of suppliers; bargaining power of buyers; and threat of substitute products. Visiongain's study is intended for anyone requiring commercial analyses for the clinical nutrition market. You find data, trends and predictions. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 Abbott Alere Inc Astellas Baxter Healthcare Beverage Partners Worldwide Biersdorf Braun Melsungen AG Bristol-Myers Squibb Cereal Partners Worldwide Chuv Lausanne Dairy Partners Americas Elli Lilly Fresenius Kabi Gerber Gillette GlaxoSmithKline (GSK) Groupe Danone Heinz Hipp Hormel Health Lab Hospira Immunocal Immunotech Research Institut national de la recherche agronomique (INRA) Kanebo Kao Massey Mead Johnson Merck Nature's One Nestle Novartis Numico Nutritek Nutrition Nutritionals Otsuka Pharmaceuticals Pacific Health Pharmaceuticals Patheon Royal Numico N.V Schwartz Bio-Research SHS Smithkline St. Jude Medical, Inc. U.S. Dentek Warner Lambert Wyeth Ayerst Yale New Haven Hospital Yashili International Holdings Ltd List of Organizations Mentioned in the Report Columbia University European Medicines Agency (EMA) Food and Drug Administration (FDA) Harvard School of Nutrition Institute of Dentistry University of Turku Milk & Health Research Center United Nations Department of Economic and Social Affairs (UN-DESA) World Health Organization (WHO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 9, 2017
Site: www.prnewswire.co.uk

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 144-page report you will receive 150 charts - all unavailable elsewhere. The 144-page report provides clear detailed insight into the global clinical nutrition market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. • This report also shows forecast revenue to 2027 for the leading segments and sub segments of the clinical nutrition market: • Our analyses show individual revenue forecasts to 2027 for these regional and national markets: - North America: the US and Rest of North America - Europe: Germany, France, the UK and Rest of Europe - Asia-Pacific: China, Japan, India and Rest of Asia-Pacific - Rest of the World (RoW): Middle East and Rest of RoW Each regional market is further segmented into the leading segments and sub segments of the clinical nutrition market. Whereas, each national market is further segmented into the leading segments of the clinical nutrition market. • This report discusses the leading companies that hold the majority of market shares in the clinical nutrition market: - Baxter International. NYSE: BAX - Abbott Laboratories. NYSE: ABT - B. Braun Melsungen AG. - Nestle S.A. VTX: NESN - Groupe Danone. EPA: BN - Mead Johnson. NYSE: MJN - Fresenius Kabi. ETR: FRE - Hospira. NYSE: HSP - Perrigo. TLV: PRGO • This report also discusses Porter's Five Forces Analysis. These forces analyze the clinical nutrition market from five different perspectives such as competitive rivalry within the industry; threat of new entrants; bargaining power of suppliers; bargaining power of buyers; and threat of substitute products. Visiongain's study is intended for anyone requiring commercial analyses for the clinical nutrition market. You find data, trends and predictions. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 Abbott Alere Inc Astellas Baxter Healthcare Beverage Partners Worldwide Biersdorf Braun Melsungen AG Bristol-Myers Squibb Cereal Partners Worldwide Chuv Lausanne Dairy Partners Americas Elli Lilly Fresenius Kabi Gerber Gillette GlaxoSmithKline (GSK) Groupe Danone Heinz Hipp Hormel Health Lab Hospira Immunocal Immunotech Research Institut national de la recherche agronomique (INRA) Kanebo Kao Massey Mead Johnson Merck Nature's One Nestle Novartis Numico Nutritek Nutrition Nutritionals Otsuka Pharmaceuticals Pacific Health Pharmaceuticals Patheon Royal Numico N.V Schwartz Bio-Research SHS Smithkline St. Jude Medical, Inc. U.S. Dentek Warner Lambert Wyeth Ayerst Yale New Haven Hospital Yashili International Holdings Ltd List of Organizations Mentioned in the Report Columbia University European Medicines Agency (EMA) Food and Drug Administration (FDA) Harvard School of Nutrition Institute of Dentistry University of Turku Milk & Health Research Center United Nations Department of Economic and Social Affairs (UN-DESA) World Health Organization (WHO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 23, 2017
Site: www.businesswire.com

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the following changes to its executive leadership team: Ludwig Hantson, Alexion’s Chief Executive Officer, stated, “ We are delighted to welcome Brian to Alexion as our new Chief Commercial Officer and look forward to his leadership in developing and executing our strategies for long-term growth as we focus on creating value for all stakeholders. He brings to Alexion the expertise and proven track record that will help us continue to build on our global leadership position, as well as a passion for developing talent and cultivating a high-performing culture. At the same time, we thank Carsten for his many contributions to Alexion’s success over the past three years. He has played a critical role in bringing Alexion’s innovative therapies to patients with rare and devastating diseases around the world and establishing a solid foundation for the future.” Mr. Goff said, “ I am very excited to join Alexion and have long admired the Company’s leadership in rare diseases, commitment to breakthrough medical innovation, patient-centric focus, and successful growth trajectory. I look forward to leading the Commercial organization and to being part of the team that will take Alexion to its next chapter of growth.” With respect to Dave Anderson, Dr. Hantson commented, “ I have valued Dave’s partnership and we are grateful for his many contributions to the Company and the finance function during an important transition period. We also appreciate his continued dedication to Alexion as our active CFO until the end of August, at which time it is our expectation that we will have retained a new, world-class CFO.” Mr. Anderson added, “ With Ludwig now firmly onboard as our CEO and Alexion off to a strong start in 2017, this presents the opportunity for the Company to identify a top-talent CFO who can partner with Ludwig to drive growth and profitability over the long term. I look forward to supporting Alexion and the team in the coming months to execute a seamless transition.” With respect to identifying a new Head of R&D, Dr. Hantson said, “ The R&D function at Alexion is core to our business and to our future, and it is our intent to recruit a new Head of R&D who can build on Martin’s successes. During his time at Alexion, Martin distinguished himself as a leader in researching and developing promising therapies for rare diseases while building an outstanding R&D leadership team and organization. Martin also led the development of Strensiq, bringing the first enzyme replacement therapy to market for patients with hypophosphatasia, and significantly advanced our complement pipeline programs. All of us at Alexion appreciate his dedication to patients and his efforts to position Alexion on the leading edge of innovation as we work to address some of the rarest, life-threatening conditions.” Commenting on a new Head of Human Resources, Dr. Hantson said, “ As Alexion advances our pipeline and commercial growth priorities, we will appoint a new Head of Human Resources who will leverage Clare’s achievements in attracting and retaining the highest levels of talent required to serve patients across the globe. Since she joined the Company in 2011, Alexion has grown from approximately 800 to 3,000 employees, and we are grateful for Clare’s leadership in helping us design the structure and systems to operate globally in 50 countries. In addition, she significantly expanded our global talent initiatives, including talent management, training and development, and compensation and benefits. The Alexion team wishes Clare well and thanks her for her commitment to our mission and our people.” Mr. Goff is a proven global biopharmaceutical executive with a 25-year track record of consistently delivering sustainable growth through multiple business cycles. He has deep expertise in commercial operations across multiple therapeutic areas, as well as broad experience in managing a range of functions, including R&D, Medical Affairs, Manufacturing and Quality with a number of industry-leading biopharmaceutical companies. Most recently, Mr. Goff served as Chief Operating Officer and a Member of the Board of Directors of Neurovance, Inc., from December 2016 until the company was acquired by Otsuka Pharmaceuticals Co. in March 2017. Previously, Mr. Goff served as Baxalta’s Executive Vice President & President – Hematology Division, from the time of the company’s spin-off from Baxter International Inc. in 2015 until its combination with Shire in mid-2016. From June 2012-December 2014, he served with Baxter Healthcare Corporation as Global Hemophilia Franchise Head. Earlier in his career, Mr. Goff held positions of increasing responsibility in sales and marketing roles with Novartis Pharmaceuticals, and the pharmaceutical division of Johnson & Johnson. He earned his M.B.A. from the Wharton School at the University of Pennsylvania and his B.A. from Skidmore College. Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. In addition, Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Alexion is advancing its rare disease pipeline with highly innovative product candidates in multiple therapeutic areas. This press release and further information about Alexion can be found at: www.alexion.com. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements often include words such as "anticipate," "believe," "expect," "will," or similar expressions. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, risks related to potential disruptions to our business as a result of leadership changes, and a variety of other risks set forth from time to time in Alexion's filings with the U.S. Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended March 31, 2017 and in our other filings with the U.S. Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.


Nakajima K.,Gunma University | Nakajima K.,Otsuka Pharmaceuticals Co. | Nakajima K.,Kanazawa University | Nakajima K.,University of California at Davis | And 16 more authors.
Clinica Chimica Acta | Year: 2011

Since Zilversmit first proposed postprandial lipemia as the most common risk of cardiovascular disease, chylomicrons (CM) and CM remnants have been thought to be the major lipoproteins which are increased in the postprandial hyperlipidemia. However, it has been shown over the last two decades that the major increase in the postprandial lipoproteins after food intake occurs in the very low density lipoprotein (VLDL) remnants (apoB-100 particles), not CM or CM remnants (apoB-48 particles). This finding was obtained using the following three analytical methods; isolation of remnant-like lipoprotein particles (RLP) with specific antibodies, separation and detection of lipoprotein subclasses by gel permeation HPLC and determination of apoB-48 in fractionated lipoproteins by a specific ELISA. The amount of the apoB-48 particles in the postprandial RLP is significantly less than the apoB-100 particles, and the particle sizes of apoB-48 and apoB-100 in RLP are very similar when analyzed by HPLC. Moreover, CM or CM remnants having a large amount of TG were not found in the postprandial RLP. Therefore, the major portion of the TG which is increased in the postprandial state is composed of VLDL remnants, which have been recognized as a significant risk for cardiovascular disease. © 2011 Elsevier B.V.


Imagawa M.,University of Fukui | Takahashi S.,University of Fukui | Zenimaru Y.,University of Fukui | Kimura T.,University of Fukui | And 9 more authors.
Clinica Chimica Acta | Year: 2012

Background: Comparison of the reactivity of remnant-like lipoprotein particles (RLP) and LDL particles to LDL receptor and VLDL receptor has not been investigated. Methods: LDL receptor- or VLDL receptor-transfected ldlA-7, HepG2 and L6 cells were used. Human LDL and rabbit β-VLDL were isolated by ultracentrifugation. Human RLP was isolated using an immunoaffinity mixed gel. The effect of statin on lipoprotein receptors was examined. Results: Both LDL receptor and VLDL receptor recognized RLP. In LDL receptor transfectants, RLP, β-VLDL and LDL all bound to LDL receptor. Cold RLP competed efficiently with DiI-β-VLDL; however, cold LDL competed weakly. In VLDL receptor transfectants, RLP and β-VLDL bound to VLDL receptor, but not LDL. RLP bound to VLDL receptor with higher affinity than β-VLDL because of higher apolipoprotein E in RLP. LDL receptor expression was induced in HepG2 by the low concentration of statin while VLDL receptor expression was induced in L6 myoblasts at higher concentration. Conclusions: RLP are bound to hepatic LDL receptor more efficiently than LDL, which may explain the mechanism by which statins prevent cardiovascular risk by primarily reducing plasma RLP rather than by reducing LDL. Additionally, a high-dose of statins also may reduce plasma RLP through muscular VLDL receptor. © 2011 Elsevier B.V.

Loading Otsuka Pharmaceuticals Co. collaborators
Loading Otsuka Pharmaceuticals Co. collaborators